Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Diseases
97%
Malignant Neoplasm
97%
Clinical Trial
90%
Nonhodgkin Lymphoma
89%
Pancreas Adenocarcinoma
82%
Rituximab
78%
Neoplasm
77%
Alisertib
75%
Adverse Event
63%
Chronic Lymphatic Leukemia
59%
Protein Kinase B
58%
Monoclonal Antibody
48%
Pharmacokinetics
47%
Multiple Myeloma
47%
Tolerability
45%
Gemcitabine
42%
Aurora Kinase
40%
Myelodysplastic Syndrome
40%
Diffuse Large B Cell Lymphoma
39%
Pancreas Cancer
39%
Maximum Tolerated Dose
39%
Pharmacodynamics
38%
Hematologic Malignancy
33%
Vincristine
33%
Aurora Kinase Inhibitor
31%
Progression Free Survival
30%
Phosphotransferase Inhibitor
30%
[1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate
30%
Prostate Cancer
30%
Ibrutinib
30%
Ublituximab
30%
Carcinogenesis
29%
Tumor Growth
29%
Mantle Cell Lymphoma
29%
Chemotherapy Regimens
29%
Immune Checkpoint Inhibitor
29%
Lenalidomide
29%
Bevacizumab
28%
Ovary Cancer
27%
Aurora A Kinase
26%
Antitumor Activity
25%
Gastrointestinal Stromal Tumor
25%
Protein Tyrosine Kinase
24%
Anemia
24%
Pleckstrin
24%
Diarrhea
23%
B Cell Lymphoma
22%
Metastatic Colorectal Cancer
22%
Drug Development
22%
Medicine and Dentistry
Non-Hodgkin Lymphoma
82%
Diseases
71%
Alisertib
70%
Pancreas Adenocarcinoma
66%
Neoplasm
62%
Clinical Trial
58%
Malignant Neoplasm
49%
T Cell
48%
Peripheral T-Cell Lymphoma
42%
Tumor
41%
Pembrolizumab
41%
Adverse Event
41%
B-Cell Chronic Lymphocytic Leukemia
40%
Multiple Myeloma
40%
Cancer
37%
Diffuse Large B-Cell Lymphoma
36%
Next Generation Sequencing
35%
Chemotherapy
34%
Programmed Death-Ligand 1
33%
Oncology
31%
COVID-19
30%
Myelodysplastic Syndrome
30%
Lenalidomide
29%
B Cell
28%
Overall Survival
26%
Solid Malignant Neoplasm
26%
Progression Free Survival
26%
Anemia
25%
Cisplatin
25%
Ovarian Cancer
25%
Immune Checkpoint Inhibitor
25%
Biological Marker
24%
Genetics
23%
Polyploidy
23%
Aurora A Kinase
22%
Rituximab
22%
Targeted Therapy
22%
Aurora Kinase
22%
Cell-Free DNA
21%
Thrombocytopenia
20%
Circulating Tumor DNA
20%
Ublituximab
20%
Cyclic AMP Dependent Protein Kinase
20%
Platinum
20%
Malignant Peripheral Nerve Sheath Tumor
20%
Immunotherapy
19%
Gemcitabine
19%
Phosphotransferase Inhibitor
19%
Pancreas Cancer
18%
Programmed Cell Death
17%
Biochemistry, Genetics and Molecular Biology
Small Molecule
51%
Clinical Trial
48%
B Cell
48%
Amino Acids
41%
Platelet-Derived Growth Factor
40%
Pleckstrin Homology Domain
40%
Protein Kinase B
38%
Drug Development
37%
Programmed Cell Death
37%
C-Terminus
37%
Phosphotransferase
35%
Kinase
35%
Tumor Progression
33%
Polyploid
33%
Cancer Cell
32%
Receptor Tyrosine Kinase
31%
Platelet-Derived Growth Factor Receptor
31%
Carcinogenesis
30%
Integrin
30%
Crystallin
30%
Drug Resistance
29%
Genomics
29%
Phosphoinositide 3-Kinase
28%
Signal Transduction
27%
N-Terminus
26%
Peptide
25%
Next Generation Sequencing
25%
Gene Mutation
24%
Amyloid Protein
24%
Xenopus
23%
Molecular Model
22%
Cytokine
21%
Monoclonal Antibody
21%
Immunoglobulin Domain
20%
Receptor Tyrosine Kinase Inhibitors
20%
RAD51
20%
Abrus
20%
Microsatellite
20%
Multidrug Resistance
20%
Amyloidogenesis
20%
Circulating Tumor DNA
20%
Overall Survival
19%
Cell Survival
18%
Insulin
18%
SH2 Domain
18%
Thrombocytopenia
18%
Binding Site
18%
Antineoplastic Activity
18%
Blood Plasma
17%
Targeted Therapy
17%
